On Oct. 8, 2020, Caladrius Biosciences announced that it had opened its proof-of-concept study of CLBS119 as a treatment for COVID-19-induced lung damage and begun screening prospective patients for inclusion at NYU Langone Health.

This planned 12-patient open-label clinical trial is designed to evaluate the safety and efficacy of a single administration of CLBS119 (peripheral blood-derived autologous CD34+ cells) for the treatment and repair of COVID-19-induced lung damage in adults. The study will target patients who are experiencing hypoxia due to prior infection with SARS-CoV-2 and who require supplemental oxygen.